For the high genetic barrier agent ACH-3422, replicon RNA extracted from a pool of colonies was transfected into na’fve host cells for a second round of selection. Individual colonies recovered from first-round or second-round selection were subjected to genotypic and phenotypic studies. Results: After a single round of sovaprevir selection, the signature NS3 resistance mutations R155K or D168A/H/V/Y were readily identified in the majority of recovered colonies. In contrast, the signature NS5B resistance mutation S282T was identified in fewer than 5% of colonies

following one round of ACH-3422 selection. This incidence however increased to 77% when recovered replicon RNA was transfected into Selleck Gefitinib na’fve host cells for a second round of ACH-3422 selection. Most colonies recovered from the first round of ACH-3422 selection showed little or no

reduction in ACH-3422 susceptibility and, in addition, the observed reductions were not transmitted with the replicon RNA into the new host cells. Hence, host cell adaptation likely was the predominant mechanism for the recovery of first-round colonies. Conclusions: We present a tandem selection method in which HCV replicon RNA recovered following selection is transferred to na’ve host cells for a second round of selection. For compounds facing a high genetic barrier to resistance, this approach can greatly enhance detection of resistance mutations while attenuating the selection of host cell adaptations. Disclosures: Mingjun Huang – Employment: Achillion Pharmaceuticals, Achillion Pharmaceuticals Wengang Yang – Employment: Pembrolizumab research buy Achillion Pharmaceuticals; Stock Shareholder: Achillion Pharmaceuticals The following people have nothing to disclose: Joanne L. Fabrycki, Yongsen Zhao, Dharaben Patel, Lingling Jia, Guangwei Yang, Steven Podos, Avinash Sinomenine Phadke Background: Nucleotide analog HCV polymerase inhibitors have demonstrated a high barrier to resistance

and have emerged as a key component of some interferon-free combination regimens for the treatment of chronic hepatitis C (CHC). We identified AL-516 as part of an effort to advance potential medicines for the treatment of CHC. AL-516 is a novel, potent guanosine based nucleotide analog that demonstrates a desirable preclinical profile. Methods: The antiviral activity and selectivity of AL-516 were evaluated using the HCV repli-con system encoding NS5B sequences from multiple genotypes and resistant variants. In addition, AL-516 was profiled for effects on cell viability and mitochondrial toxicity. The nucleo-side 5′-triphosphate (AL-516 NTP) was tested against the HCV polymerase NS5B including the S282T variant, and for selectivity against human DNA and RNA polymerases. Gel-based NS5B NTP incorporation assays were conducted using the AL-516 NTP to assess the mechanism of action of the compound.